<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00417222</url>
  </required_header>
  <id_info>
    <org_study_id>2006-179</org_study_id>
    <nct_id>NCT00417222</nct_id>
  </id_info>
  <brief_title>Supplemental Benefit of Angiotensin Receptor Blocker in Hypertensive Patients With Stable Heart Failure Using Olmesartan</brief_title>
  <acronym>SUPPORT</acronym>
  <official_title>Supplemental Benefit of Angiotensin II Receptor Blocker in Hypertensive Patients With Stable Heart Failure Using Olmesartan (SUPPORT Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tohoku University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tohoku University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate whether an angiotensin II receptor blocker
      (olmesartan), in addition to conventional treatment, will reduce the mortality and morbidity
      in hypertensive patients with stable chronic heart failure.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A composite of the following outcomes 1) all-cause death 2) nonfatal acute myocardial infarction 3) nonfatal stroke 4) hospital admission due to congestive heart failure</measure>
    <time_frame>by the end of the study</time_frame>
    <description>All the patients were enrolled by March, 2010, and were followed-up by the end of March, 2013.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>cardiovascular death</measure>
    <time_frame>by the end of the study</time_frame>
    <description>All the patients were enrolled by March, 2010, and were followed-up by the end of March, 2013.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>death due to heart failure</measure>
    <time_frame>by the end of the study</time_frame>
    <description>All the patients were enrolled by March, 2010, and were followed-up by the end of March, 2013.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sudden death</measure>
    <time_frame>by the end of the study</time_frame>
    <description>All the patients were enrolled by March, 2010, and were followed-up by the end of March, 2013.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>acute myocardial infarction</measure>
    <time_frame>by the end of the study</time_frame>
    <description>All the patients were enrolled by March, 2010, and were followed-up by the end of March, 2013.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stroke</measure>
    <time_frame>by the end of the study</time_frame>
    <description>All the patients were enrolled by March, 2010, and were followed-up by the end of March, 2013.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospital admission from any cardiovascular reasons</measure>
    <time_frame>by the end of the study</time_frame>
    <description>All the patients were enrolled by March, 2010, and were followed-up by the end of March, 2013.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fatal arrhythmia or appropriate ICD discharge</measure>
    <time_frame>by the end of the study</time_frame>
    <description>All the patients were enrolled by March, 2010, and were followed-up by the end of March, 2013.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>new-onset diabetes</measure>
    <time_frame>by the end of the study</time_frame>
    <description>All the patients were enrolled by March, 2010, and were followed-up by the end of March, 2013.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>development of renal failure</measure>
    <time_frame>by the end of the study</time_frame>
    <description>All the patients were enrolled by March, 2010, and were followed-up by the end of March, 2013.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>new-onset atrial fibrillation</measure>
    <time_frame>by the end of the study</time_frame>
    <description>All the patients were enrolled by March, 2010, and were followed-up by the end of March, 2013.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>a need to modify treatment procedures for heart failure</measure>
    <time_frame>by the end of the study</time_frame>
    <description>All the patients were enrolled by March, 2010, and were followed-up by the end of March, 2013.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>left ventricular ejection fraction</measure>
    <time_frame>by the end of the study</time_frame>
    <description>All the patients were enrolled by March, 2010, and were followed-up by the end of March, 2013.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>B-type natriuretic peptide</measure>
    <time_frame>by the end of the study</time_frame>
    <description>All the patients were enrolled by March, 2010, and were followed-up by the end of March, 2013.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>serum markers for metabolic syndrome</measure>
    <time_frame>three years</time_frame>
    <description>Blood sampling was performed at the time of and 3 years after randomization. Changes in serum levels of markers for metabolic syndrome (high sensitive C-reactive protein, adiponectin, microRNAsï¼‰ were examined .</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1145</enrollment>
  <condition>Chronic Heart Failure</condition>
  <arm_group>
    <arm_group_label>Olmesartan medoxomil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>olmesartan medoxomil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olmesartan medoxomil</intervention_name>
    <description>5 to 40mg P.O. daily until the end of the study</description>
    <arm_group_label>Olmesartan medoxomil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients who meet all of the following criteria.

          -  Patients with NYHA class II through IV chronic heart failure.

          -  Patients who have a history of hypertension or those who have antihypertensive
             medications.

          -  Patients who are aged 20 years or older and less than 80 years at the entry.

          -  Stable patients who have angiotensin converting enzyme inhibitor and/or beta-blocker.

          -  Patients who do not have angiotensin II receptor blocker.

        Exclusion Criteria:

          -  Patients who have renal dysfunction (serum creatinine &gt;=3.0mg/dL) or those who are
             receiving chronic hemodialysis.

          -  History of drug hypersensitivity to olmesartan.

          -  Patients who have severe liver dysfunction.

          -  History of angioedema.

          -  History of malignant tumor or life-threatening illness of poor prognosis.

          -  Pregnant or possibly pregnant patients.

          -  Cardiovascular surgery within 6months prior to the date of the entry.

          -  Acute myocardial infarction within 6 months prior to the date of the entry.

          -  Percutaneous coronary intervention or stent implantation within 6 months prior to the
             date of the entry.

          -  Other patients deemed unsuitable as subjects of the study by the treating physician.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hiroaki Shimokawa, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine</name>
      <address>
        <city>Sendai-city</city>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://tohoku.cardiovascular-medicine.jp</url>
    <description>Click here for more information about this study: SUPPORT Trial</description>
  </link>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 28, 2006</study_first_submitted>
  <study_first_submitted_qc>December 28, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2006</study_first_posted>
  <last_update_submitted>May 16, 2014</last_update_submitted>
  <last_update_submitted_qc>May 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tohoku University</investigator_affiliation>
    <investigator_full_name>Hiroaki Shimokawa, MD, PhD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olmesartan</mesh_term>
    <mesh_term>Olmesartan Medoxomil</mesh_term>
    <mesh_term>Angiotensin Receptor Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

